Published in Drug Week, June 11th, 2004
Under an Investigational New Drug application (IND) submitted to the U.S. Food and Drug Administration (FDA), the multi-national clinical trial will assess the efficacy and safety of Gamunex, Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified, in RRMS. The study includes 120 patients participating from many regions of the world, including North America, eastern and western Europe, and Israel.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.